HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

R Vigneri Selected Research

Transcription Factors (Transcription Factor)

9/2013Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


R Vigneri Research Topics

Disease

10Neoplasms (Cancer)
01/2020 - 01/2001
9Insulin Resistance
12/2013 - 01/2000
7Thyroid Neoplasms (Thyroid Cancer)
12/2017 - 06/2001
4Obesity
11/2016 - 11/2000
2Type 2 Diabetes Mellitus (MODY)
05/2018 - 08/2000
2Carcinogenesis
12/2017 - 01/2001
2Hyperinsulinism (Hyperinsulinemia)
12/2016 - 01/2000
2Papillary Carcinoma
08/2001 - 06/2001
1Metabolic Diseases (Metabolic Disease)
01/2020
1Neuroendocrine Tumors (Neuroendocrine Tumor)
02/2015
1Rare Diseases (Rare Disease)
02/2015
1Inflammation (Inflammations)
09/2013
1Spontaneous Remission
03/2007
1Chronic Kidney Failure (Chronic Renal Failure)
03/2007
1Necrobiosis Lipoidica
03/2007
1Cicatrix (Scar)
03/2007
1Aggressive Fibromatosis (Desmoid)
01/2006
1Goiter
01/2006
1Adenoma (Adenomas)
01/2006
1Deglutition Disorders (Dysphagia)
01/2006
1Pain (Aches)
01/2006
1Hyperglycemia
07/2003
1Hypothyroidism
11/2001
1Neoplasm Metastasis (Metastasis)
11/2001
1Nodular Goiter
08/2001
1Morbid Obesity
11/2000
1Cardiovascular Diseases (Cardiovascular Disease)
08/2000
1Insulinoma
01/2000
1Hepatocellular Carcinoma (Hepatoma)
01/2000

Drug/Important Bio-Agent (IBA)

8Insulin (Novolin)FDA Link
01/2020 - 01/2000
8Insulin ReceptorIBA
12/2016 - 01/2000
5Glucose (Dextrose)FDA LinkGeneric
05/2018 - 01/2000
5Protein Isoforms (Isoforms)IBA
12/2016 - 01/2001
4Proteins (Proteins, Gene)FDA Link
03/2007 - 01/2000
3IGF Type 1 Receptor (IGF 1 Receptor)IBA
12/2016 - 11/2000
2Biological ProductsIBA
01/2018 - 11/2016
2Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
08/2001 - 06/2001
2Phosphotransferases (Kinase)IBA
06/2001 - 01/2000
2Insulin-Like Growth Factor I (IGF-1)IBA
06/2001 - 11/2000
2Insulin-Like Growth Factor II (Somatomedin A)IBA
06/2001 - 01/2001
1Long-Acting Insulin (Insulin, Long Acting)FDA Link
01/2018
1Insulin Glargine (Lantus)FDA Link
01/2018
1Heavy MetalsIBA
12/2017
1MineralsIBA
02/2015
1AdiponectinIBA
12/2013
1Reactive Oxygen Species (Oxygen Radicals)IBA
09/2013
1CytokinesIBA
09/2013
1Estrogens (Estrogen)FDA Link
09/2013
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
09/2013
1Transcription Factors (Transcription Factor)IBA
09/2013
1MitogensIBA
09/2013
1Tacrolimus (Prograf)FDA LinkGeneric
03/2007
1Mycophenolic Acid (Cellcept)FDA LinkGeneric
03/2007
1Prednisone (Sone)FDA LinkGeneric
03/2007
1ThyroglobulinFDA Link
01/2006
1Colloids (Colloid)IBA
01/2006
1PPAR gammaIBA
11/2003
1Glucosamine (Dona)IBA
09/2003
1Thyrotropin AlfaFDA LinkGeneric
11/2001
1Amino AcidsFDA Link
11/2001
1Thyrotropin (Thyroid-Stimulating Hormone)FDA Link
11/2001
1Thyroxine (Levothyroxine)FDA LinkGeneric
11/2001
1N 30IBA
08/2001
1CholesterolIBA
08/2001
1HDL CholesterolIBA
08/2001
1ectonucleotide pyrophosphatase phosphodiesterase 1IBA
08/2001
1Proto-Oncogene Proteins c-metIBA
08/2001
1Messenger RNA (mRNA)IBA
08/2001
1Imatinib Mesylate (Gleevec)FDA Link
06/2001
1Tyrosine (L-Tyrosine)FDA Link
06/2001
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2001
1Tyrosine Kinase InhibitorsIBA
06/2001
1Insulin-Like PeptidesIBA
06/2001
1Lysine (L-Lysine)FDA Link
04/2001
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
04/2001
1Glutamine (L-Glutamine)FDA Link
04/2001
1ImmunosorbentsIBA
11/2000
1EnzymesIBA
11/2000
1GlycogenIBA
01/2000

Therapy/Procedure

3Thyroidectomy
11/2017 - 01/2006
2Therapeutics
12/2016 - 03/2007
1Skin Transplantation (Skin Grafting)
03/2007
1Kidney Transplantation
03/2007
1Glycemic Control
08/2000